Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer.

Download DocumentationJuno Corporate Presentation - August 2016
Webcast ImageWebcast - Replay
Q2 2016 Juno Therapeutics Earnings Conference Call
August 04, 2016 at 2:00 p.m. PT
Q2 2016 Juno Therapeutics Earnings Conference Call
Thursday, August 4, 2016 2:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Recent News

DateTitle 
Aug. 04, 2016Juno Therapeutics Reports Second Quarter 2016 Financial ResultsPrinter Friendly Version
Aug. 04, 2016Juno Therapeutics Announces Multiple Myeloma Partnership with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for Developing CAR T Cell Immunotherapy Against Multiple Novel TargetsPrinter Friendly Version
Jul. 28, 2016Juno Therapeutics to Report Second Quarter 2016 Financial Results on Thursday, August 4Printer Friendly Version
Jul. 14, 2016Juno Therapeutics Adds Adenosine Receptor Antagonist Through Acquisition of RedoxTherapiesPrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Past Events

DateTitle
08/04/16 2:00 p.m. PT
Q2 2016 Juno Therapeutics Earnings Conference Call
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
JUNO (Common Stock)
ExchangeNASDAQ
Price$31.53
Change Stock is Down 0.28 (0.88%)
Volume654,203
Data as of Aug. 30, 2016 4:00 p.m. ET